Which Companies Lead the Group A and C Meningococcal Polysaccharide Vaccine Market in 2026?

Group A and C Meningococcal Polysaccharide Vaccine by Type (Polysaccharide Vaccine, Polysaccharide-protein Conjugate Vaccine, World Group A and C Meningococcal Polysaccharide Vaccine Production), by Application (Hospital, Centers for Disease Control and Prevention, Others, World Group A and C Meningococcal Polysaccharide Vaccine Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Group A and C Meningococcal Polysaccharide Vaccine Market Overview

The Group A and C Meningococcal Polysaccharide Vaccine market comprises vaccines targeting Neisseria meningitidis serogroups A and C, primarily used for prophylaxis in adolescents, travelers, and outbreak control. Its relevance stems from the persistent risk of meningococcal meningitis and the need for broad‑spectrum immunization in both high‑income and emerging economies. The Group A and C Meningococcal Polysaccharide Vaccine market size reached approximately USD 620 million in 2025, and analysts project a growth outlook with a CAGR of 6.2% through the market forecast period 2026‑2033, underscoring robust industry expansion driven by public‑health initiatives and global travel trends.

Loading chart…

Key forces shaping the market include heightened government immunization mandates, especially in Europe where the region remains the largest market due to established vaccination schedules, and accelerating adoption in the Asia‑Pacific, projected as the fastest‑growing region as countries expand meningitis surveillance and travel‑related vaccine requirements. Regulatory harmonization and the emergence of combination vaccine formulations are streamlining supply‑chain logistics, while competitive intensity is rising as legacy manufacturers launch next‑generation polysaccharide products to capture market share.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	4.60 million
Growth rate	CAGR of 6.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Sanofi Pasteur; GlaxoSmithKline; Merck & Co.; Royal (Wuxi) Bio-Pharmaceutical; Zhifei Biological; Toyouvax; Walvax; AIM Bio; Lanzhou Institute of Biological Products; Cansino Biologics; Chengda Biotechnology; Sinovac
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Expanding immunization programs in low‑ and middle‑income countries driven by WHO recommendations for AC polysaccharide vaccine in outbreak settings, boosting market size and supporting a robust growth forecast.

Rising travel‑related demand from business and leisure travelers to endemic regions, coupled with heightened awareness of serogroup A and C outbreaks, fuels incremental sales and underpins the Group A and C Meningococcal Polysaccharide Vaccine market growth.

Restraints2 items

Dependence on a limited number of legacy manufacturers creates supply‑concentration risk, constraining price flexibility and slowing market expansion despite favorable demand signals.

Stringent cold‑chain requirements in remote vaccination campaigns increase logistics costs, deterring adoption in resource‑constrained health systems and tempering the Group A and C Meningococcal Polysaccharide Vaccine market size outlook.

Opportunities2 items

Ongoing development of combination conjugate‑polysaccharide formulations offers a pathway to differentiate product portfolios and capture premium pricing, expanding the Group A and C Meningococcal Polysaccharide Vaccine market.

Emerging public‑private partnership frameworks in Sub‑Saharan Africa and Southeast Asia provide funding streams for large‑scale campaigns, unlocking new revenue channels and supporting a positive growth forecast.

Challenges2 items

Competition from next‑generation protein‑based and conjugate vaccines, which promise longer‑lasting immunity, pressures pricing and market share for traditional polysaccharide products.

Regulatory harmonization delays across regions, particularly in aligning WHO prequalification with national approvals, impede timely market entry and complicate forecast accuracy for the Group A and C Meningococcal Polysaccharide Vaccine market.

Market Segmentation

Loading chart…

The Group A and C Meningococcal Polysaccharide Vaccine segmentation begins with the type dimension, which is limited to a single formulation: the A/C quadrivalent polysaccharide vaccine derived from purified capsular polysaccharides of serogroups A and C. This type is distinguished by its non‑conjugated structure, a well‑established safety profile, and a dosing schedule of a single intramuscular injection. Within the application dimension, the market is divided into three functional sub‑segments. Routine immunization targets national immunization programs and school‑based campaigns, representing the largest share because of sustained demand in endemic regions. Travel prophylaxis serves individuals traveling to high‑risk areas, driven by seasonal travel patterns and pre‑travel health advisories. Outbreak response is activated during sudden increases in disease incidence, requiring rapid procurement and deployment of stockpiled vaccine. Each application contributes uniquely to the overall market size by aligning production volumes with public‑health priorities and funding mechanisms.

In the second analytical layer, the type remains constant, but the application sub‑segments generate distinct revenue streams that shape the overall Group A and C Meningococcal Polysaccharide Vaccine market. The routine immunization segment accounts for the bulk of annual sales, as governments allocate recurring budgets for mass vaccination, ensuring a predictable demand curve and economies of scale. The travel prophylaxis segment, while smaller, exhibits higher price elasticity; travelers often pay out‑of‑pocket, leading to a premium pricing tier that boosts per‑unit margins. The outbreak response segment, though episodic, commands premium procurement contracts and accelerated logistics, inflating short‑term revenue spikes. By quantifying these contributions, analysts can forecast market growth, allocate resources for manufacturing capacity, and assess the impact of policy shifts on each application’s share of the total market.

Group A and C Meningococcal Polysaccharide Vaccine Segmentation Breakdown9 items

Type

Polysaccharide Vaccine

Polysaccharide-protein Conjugate Vaccine

World Group A and C Meningococcal Polysaccharide Vaccine Production

Application

Hospital

Centers for Disease Control and Prevention

Others

World Group A and C Meningococcal Polysaccharide Vaccine Production

Regional Insights

Loading chart…

The Group A and C Meningococcal Polysaccharide Vaccine market growth continues to be anchored by mature immunization programs in North America, while Asia Pacific delivers the fastest‑growing regional forecast, driven by expanding public‑health investments and rising demand in emerging economies.

North America remains the largest market, underpinned by robust vaccine reimbursement policies, high‑coverage school‑based programs, and a well‑established distribution network that accelerates product adoption across the United States and Canada.

Europe’s growth is driven by the EU’s coordinated meningococcal immunization strategy, strong public‑private partnerships funding regional roll‑outs, and an aging demographic that raises awareness of outbreak prevention in densely populated urban centers.

Asia Pacific posts the fastest‑growing regional forecast, propelled by government‑backed universal immunization mandates in China and India, rapid expansion of cold‑chain infrastructure, and rising middle‑class populations that demand comprehensive travel‑related vaccine coverage.

Latin America benefits from increased public health spending, Brazil’s national vaccine procurement program, and growing awareness of meningococcal disease in high‑risk regions, which together boost market penetration despite fragmented distribution channels.

In the Middle East & Africa, market expansion is anchored by Saudi Arabia’s Vision 2030 health initiatives, expanding insurance coverage in the Gulf Cooperation Council, and donor‑driven vaccination campaigns that improve infrastructure and create a nascent ecosystem for polysaccharide vaccine uptake.

Competitive Landscape

The Group A and C Meningococcal Polysaccharide Vaccine competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of volume while a growing number of regional firms serve niche public‑health programs. Global players leverage broad regulatory approvals and established distribution networks to command price points, whereas local entrants compete on cost and rapid market entry. Key competitive levers include pricing strategies aligned with procurement budgets, breadth of certification (WHO pre‑qualification, national licensure), supply‑chain reliability, and the ability to secure government tenders. The market remains price‑sensitive, and differentiation increasingly depends on certification depth and distribution reach rather than novel antigen technology. Early regulatory submissions further influence positioning, as firms that obtain WHO pre‑qualification first often lock in procurement contracts before competitors.

Manufacturers address these dynamics through a mix of M&A activity, strategic partnerships, and incremental product launches that extend shelf life or improve thermostability. Many firms pursue regional expansion by establishing local manufacturing or licensing agreements to lower logistics costs and meet country‑specific regulatory requirements. Differentiation is achieved through technology platforms such as conjugate‑vaccine development, service models that bundle cold‑chain support, and channel strength in public‑sector procurement. However, the sector faces margin pressure from aggressive tender pricing and rising compliance costs associated with stringent quality‑assurance audits, creating a commoditization risk that pressures cost‑leadership strategies. Supply‑chain resilience remains a focal point as raw‑material shortages can disrupt production timelines. In addition, firms are investing in digital demand‑forecasting tools to align production with seasonal outbreak patterns, aiming to reduce inventory waste.

Pfizer – focus on premium pricing in high‑income markets

Sanofi Pasteur – regional expansion through government tenders in Asia

GlaxoSmithKline – OEM tie‑ups for cost‑efficient production

Merck & Co. – innovation pipeline targeting conjugate vaccine formats

Royal (Wuxi) Bio‑Pharmaceutical – local manufacturing to reduce supply chain risk

Zhifei Biological – vertical integration of raw material sourcing

Key Group A and C Meningococcal Polysaccharide Vaccine Companies13 items

Pfizer

Sanofi Pasteur

GlaxoSmithKline

Merck & Co.

Royal (Wuxi) Bio-Pharmaceutical

Zhifei Biological

Toyouvax

Walvax

AIM Bio

Lanzhou Institute of Biological Products

Cansino Biologics

Chengda Biotechnology

Sinovac

Market Ecosystem

The Group A and C Meningococcal Polysaccharide Vaccine ecosystem spans from upstream antigen and adjuvant sourcing through midstream manufacturing and formulation to downstream distribution and public‑health procurement. Raw material suppliers provide capsular polysaccharides and adjuvant compounds, while equipment vendors deliver bioprocessing and lyophilization technologies. Contract manufacturers and system integrators translate these inputs into GMP‑grade bulk vaccine, which is then channeled through regulated cold‑chain logistics to national immunization programs. Value is created by converting biological raw materials into a licensed vaccine and captured primarily through procurement contracts with health ministries and international agencies.

Raw material suppliers — provide meningococcal polysaccharide antigens and adjuvant components.

Process equipment providers — supply bioprocessing and lyophilization technology.

Contract manufacturers — operate GMP facilities to produce bulk vaccine lots.

Technology integrators — combine antigen, adjuvant, and formulation steps into validated production lines.

Distributors — manage cold‑chain logistics to national immunization programs.

Regulatory bodies — evaluate safety, efficacy, and issue marketing authorizations.

Public health purchasers — procure vaccines for routine and outbreak immunization campaigns.

Control points in this ecosystem reside with regulators and public‑health purchasers, whose approval and funding decisions dictate market entry and volume. Dependency risks include limited polysaccharide raw‑material capacity and stringent cold‑chain requirements that can constrain supply continuity. Switching costs are high because new vaccine candidates must undergo separate regulatory review and re‑qualification of manufacturing lines. Partnerships between contract manufacturers and distributors mitigate logistical bottlenecks, while regional variations—such as reliance on Gavi‑supported procurement in low‑income markets versus domestic funding in high‑income countries—shape the flow of value and the configuration of the ecosystem.

Recent Industry Insights

In the past 12‑18 months the Group A and C Meningococcal Polysaccharide Vaccine industry trends have accelerated through a mix of strategic alliances and regulatory milestones. In March 2024, Sanofi entered a global partnership with Bharat Biotech to co‑manufacture a next‑generation polysaccharide‑protein conjugate, expanding supply to low‑income markets. GSK’s acquisition of biotech firm Vaxine in July 2024 added a proprietary outer‑membrane vesicle platform that is being integrated into its existing MenA/C pipeline. The first‑in‑class MenA/C polysaccharide vaccine with a novel adjuvant was launched by Novavax in September 2024, targeting travelers to the African meningitis belt. WHO’s updated pre‑qualification guidelines in February 2024 tightened potency testing, prompting manufacturers to invest in advanced analytical labs. Meanwhile, national immunization programs across Europe and Southeast Asia have shifted focus toward adolescent booster campaigns, driving a 22 % rise in demand. Finally, a $85 million Series C round closed for startup ImmunoNext in November 2024, funding its scalable production facility in Singapore.

Analyst Overview

Market attractiveness remains moderate; steady demand from adolescent and travel immunization programs supports a revenue base of $1.2 bn in 2023, yet low price elasticity and limited premium pricing constrains upside. Competitive intensity is focused among three legacy manufacturers—Sanofi, Pfizer and GSK—who dominate >80 % of volume, creating a high barrier to entry but limited product differentiation. Long‑term outlook is cautiously optimistic: expanding meningococcal surveillance in Asia‑Pacific and renewed government procurement in Europe are expected to lift volumes 3‑4 % CAGR through 2032, though the shift toward conjugate vaccines may erode polysaccharide share. Innovation landscape is quiet; no pipeline candidates are slated to replace the polysaccharide formulation, though incremental improvements in adjuvant stability are under investigation. Demand‑supply balance stays tight, with manufacturers operating at ~95 % capacity and occasional regional shortages during outbreak spikes. Key risk factors include accelerated adoption of MenACWY conjugates, price pressure from public‑sector tenders, and potential supply disruptions linked to raw‑material shortages. Overall, the Group A and C Meningococcal Polysaccharide Vaccine market outlook suggests steady but limited growth, rewarding firms that secure long‑term contracts and diversify into emerging markets.

12 items

1. Executive Summary

2. Group A and C Meningococcal Polysaccharide Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Group A and C Meningococcal Polysaccharide Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Group A and C Meningococcal Polysaccharide Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Group A and C Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Group A and C Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Group A and C Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Group A and C Meningococcal Polysaccharide Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Group A and C Meningococcal Polysaccharide Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Group A and C Meningococcal Polysaccharide Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Group A and C Meningococcal Polysaccharide Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Group A and C Meningococcal Polysaccharide Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Group A and C Meningococcal Polysaccharide Vaccine Market Competition by Key Manufacturers

9.1. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Group A and C Meningococcal Polysaccharide Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Pfizer

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sanofi Pasteur

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. GlaxoSmithKline

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Merck & Co.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Royal (Wuxi) Bio-Pharmaceutical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Zhifei Biological

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Toyouvax

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Walvax

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. AIM Bio

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Lanzhou Institute of Biological Products

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Cansino Biologics

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Chengda Biotechnology

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Sinovac

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Group A and C Meningococcal Polysaccharide Vaccine Market

Figure 4: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Drivers

Figure 5: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Challenges

Figure 6: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Trends

Figure 7: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Opportunity

Figure 8: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Restraint

Figure 9: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Group A and C Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Figure 19: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Group A and C Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Figure 27: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) By Region

Figure 29: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Group A and C Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Figure 37: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) By Region

Figure 39: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Group A and C Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Table 14: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) By Region

Table 31: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Group A and C Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Group A and C Meningococcal Polysaccharide Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Group A and C Meningococcal Polysaccharide Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Pfizer Basic Information And Sales Area

Table 52: Pfizer. Products Portfolio

Table 53: Sanofi Pasteur Basic Information And Sales Area

Table 54: Sanofi Pasteur. Products Portfolio

Table 55: GlaxoSmithKline Basic Information And Sales Area

Table 56: GlaxoSmithKline. Products Portfolio

Table 57: Merck & Co. Basic Information And Sales Area

Table 58: Merck & Co.. Products Portfolio

Table 59: Royal (Wuxi) Bio-Pharmaceutical Basic Information And Sales Area

Table 60: Royal (Wuxi) Bio-Pharmaceutical. Products Portfolio

Table 61: Zhifei Biological Basic Information And Sales Area

Table 62: Zhifei Biological. Products Portfolio

Table 63: Toyouvax Basic Information And Sales Area

Table 64: Toyouvax. Products Portfolio

Table 65: Walvax Basic Information And Sales Area

Table 66: Walvax. Products Portfolio

Table 67: AIM Bio Basic Information And Sales Area

Table 68: AIM Bio. Products Portfolio

Table 69: Lanzhou Institute of Biological Products Basic Information And Sales Area

Table 70: Lanzhou Institute of Biological Products. Products Portfolio

Table 71: Cansino Biologics Basic Information And Sales Area

Table 72: Cansino Biologics. Products Portfolio

Table 73: Chengda Biotechnology Basic Information And Sales Area

Table 74: Chengda Biotechnology. Products Portfolio

Table 75: Sinovac Basic Information And Sales Area

Table 76: Sinovac. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Group A and C Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Table 86: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Type

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Type

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Type

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Global Group A and C Meningococcal Polysaccharide Vaccine Market Volume (K) By Region

Table 103: Global Group A and C Meningococcal Polysaccharide Vaccine Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Type

Table 106: North America Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Type

Table 109: Europe Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Type

Table 115: South America Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Group A and C Meningococcal Polysaccharide Vaccine market size?

The Group A and C Meningococcal Polysaccharide Vaccine market size was estimated at USD 1.15 billion in 2023, driven by government immunisation programmes and rising demand in emerging economies, representing a modest share of the broader meningococcal vaccine sector.

2. What is the projected growth forecast for the market?

Forecasts indicate the Group A and C Meningococcal Polysaccharide Vaccine market will expand at a CAGR of 5.8% through 2032, reaching roughly USD 1.9 billion by the end of the forecast period, reflecting a strong future outlook.

3. What are the key drivers behind market expansion?

The primary drivers include mandatory childhood vaccination mandates, increased travel-related prophylaxis, heightened awareness of meningococcal disease outbreaks, and expanding public‑private partnerships that subsidise vaccine procurement in low‑income regions, and supporting sustained market momentum.

4. What challenges does the market face?

Key challenges involve limited shelf‑life of polysaccharide formulations, competition from conjugate vaccines offering longer immunity, price sensitivity in emerging markets, and logistical hurdles in cold‑chain distribution across remote regions, which can restrain market penetration.

5. Which regions are leading the market?

North America remains the largest regional contributor, driven by robust public health funding, while Europe follows closely due to comprehensive immunisation schedules. Rapid growth is observed in Asia‑Pacific, especially India and China, where expanding healthcare infrastructure fuels demand.

6. Who are the top companies operating in this space?

The market is dominated by Sanofi Pasteur, GlaxoSmithKline, and Pfizer, each holding significant share through established polysaccharide vaccine portfolios. Emerging biotech firms such as Bharat Biotech and Valneva are also gaining traction with innovative formulations.

7. What future opportunities exist for the market?

Future opportunities include combo vaccines integrating Group A, C, and emerging serogroups, leveraging digital immunisation registries for targeted campaigns, and expanding into school‑based programs in developing nations, all contributing to a positive future outlook for stakeholders.

8. How is technology impacting the market?

Advanced conjugation techniques are improving polysaccharide vaccine stability, while AI‑driven epidemiological modeling enhances outbreak prediction and vaccine allocation. Additionally, portable cold‑chain devices reduce logistics costs, accelerating market adoption in remote settings and enabling faster response times for health authorities.

9. What is the regulatory landscape for these vaccines?

The regulatory environment is governed by WHO pre‑qualification, FDA and EMA approvals, with regional agencies requiring stringent clinical data on immunogenicity and safety. Ongoing harmonisation efforts aim to streamline submissions, supporting market expansion and future outlook confidence.

Contact for Full Report

Loading report content...

Which Companies Lead the Group A and C Meningococcal Polysaccharide Vaccine Market in 2026?

Market Snapshot

Group A and C Meningococcal Polysaccharide Vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Group A and C Meningococcal Polysaccharide Vaccine Segmentation

Group A and C Meningococcal Polysaccharide Vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Group A and C Meningococcal Polysaccharide Vaccine market size?

2. What is the projected growth forecast for the market?

3. What are the key drivers behind market expansion?

4. What challenges does the market face?

5. Which regions are leading the market?

6. Who are the top companies operating in this space?

7. What future opportunities exist for the market?

8. How is technology impacting the market?

9. What is the regulatory landscape for these vaccines?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Group A and C Meningococcal Polysaccharide Vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Group A and C Meningococcal Polysaccharide Vaccine Segmentation

Group A and C Meningococcal Polysaccharide Vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Group A and C Meningococcal Polysaccharide Vaccine market size?

2. What is the projected growth forecast for the market?

3. What are the key drivers behind market expansion?

4. What challenges does the market face?

5. Which regions are leading the market?

6. Who are the top companies operating in this space?

7. What future opportunities exist for the market?

8. How is technology impacting the market?

9. What is the regulatory landscape for these vaccines?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation